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Sharing benefits in international health
research
Research-capacity building as an example of an indirect collective benefit
Annette Schulz-Baldes, Effy Vayena & Nikola Biller-Andorno
O
ver the past decade, clinical
investigators and sponsors have
shown increased interest in con-
ducting clinical trials and other health-
related research in resource-poor settings,
notably Asia, Africa and South America.
This move to poorer countries can bring
many benefits: personnel costs are lower,
and it is easier to recruit participants and to
implement placebo-controlled trials that
produce less ambiguous data, which might
reduce the time it takes to approve a new
drug. For the people in these areas, partici-
pating in clinical trials or basic research is
often beneficial because it can give them
an otherwise rare opportunity to access
medical care (Ballantyne, 2005).
However, such research does not
always address local health needs.
Research participants are sometimes pro-
vided with medical care that is below the
standards of developed countries, and
drugs or therapies are not always made
available to participants and their commu-
nities once they have been authorized for
sale in North America or Europe. Although
such research usually involves some bene-
fits for participants and their communities,
these benefits can stil l be unfair when
compared with the benefits that sponsors
and future patients in wealthier countries
gain, or when the benefits do not outweigh
the risks assumed by the participants and
involved communities. In such cases, the
research is exploitative.
It has been claimed that, in order to
reduce exploitation in international health
research, sponsors should provide ‘fair’
benefits to participants and their commu-
nities (Participants, 2002, 2004). Although
there has been much debate about what
constitutes ‘fair’ research benefits, the
related practical questions have received
less attention. What is the range of possi-
ble benefits? Can they be distinguished in
ethical terms? What concrete measures
can be used to implement them in an ethi-
cally defensible way? In this article, we
discuss advantages and challenges in the
implementation of what we call ‘ indirect
collective’ research benefits in resource-
poor settings, using the example of
research-capacity building.
E
xploitative transactions are defined
by an unfair distribution of risks and
benefits among the parties involved
(Wertheimer, 1996). In the context of
international health research, this can
mean two things: study participants in
resource-poor settings assume the risks of
research, sometimes for l ittle individual
benefit, whereas patients in wealthier
countries primarily benefit from the
results; or sponsors do not provide
research participants and communities
with a fair share of the benefits or profits
after successful completion of a study.
Owing to restricted healthcare services,
limited education, cultural differences
and often fragmentary or inefficient
research regulations, there is a particular
risk of exploitation when sponsors or
investigators from wealthier countries con-
duct research in resource-poor settings
(Macklin, 2004).
Within the global community, an unfair
distribution of risks can be addressed by
limiting research to studies that respond to
the health needs of the community
(CIOMS, 2002). However, reaching a fair
distribution of research benefits between
sponsors, study participants and their
communities within the scope of a research
project is more complex, and difficult to
translate into practice. Although collective
research benefits—such as reasonable
availability of a new intervention—have
always been controversial, what we refer
to as indirect collective research benefits
pose some particular conceptual and
practical challenges.
A survey of the relevant literature and
regulations for externally sponsored
research in resource-poor settings reveals 
a recent change in what is considered a
research benefit. Previously, the ethical
acceptability of conducting research in
poorer countries was primarily framed 
in terms of its responsiveness to the health
needs and the priorities of the population or
community involved (CIOMS, 2002). This,
it was argued, not only justified selecting
the study population solely on epidemiol-
ogical grounds and in accordance with
local or regional priorities, but also
required that a proven intervention be
made available to participants and the
community after the study, and at reason-
able costs. Indeed, most of the previous
debates on research benefits revolved
around the concept of reasonable availab-
ility (Crouch & Arras, 1998; Glantz et al,
Although there has been much
debate about what constitutes
‘fair’research benefits, the
related practical questions have
received less attention
science & society
©2007 EUROPEAN MOLECULAR BIOLOGY ORGANIZATION EMBO reports   VOL 8 | NO 1 | 2007
viewp o in t
9
1998) and the standards of care provided to
participants during a study (Macklin, 2004;
Wendler et al, 2004). Current international
guidelines and recommendations on 
clinical research in developing countries
emphasize the same points (WHO, 2000;
CIOMS, 2002; WMA, 2002).
H
owever, the main focus on ‘rea-
sonable availabil i ty’ was criti-
cized by an international working
group convened in 2001 by the US
National Institutes of Health (Bethesda,
MD, USA) and the University of Malawi
(Blantyrem, Malawi) for being both too
narrow and conceptually misleading
(Participants, 2002, 2004). Instead, the
group proposed a broader framework of
‘fair benefits’ to include not only medical
treatment of participants during the study
and availabil i ty of the proven intervention
afterwards, but also collateral health ser-
vices, public-health measures, employ-
ment and economic activity, capacity
development and financial rewards.
The argument in favour of expanding
the range of possible research benefits
was that making an intervention reason-
ably available after the successful comple-
tion of a study was not a sufficient 
safeguard against exploitation, for both
empirical and conceptual reasons
(Participants, 2002, 2004). Empirically, it
was argued, much clinical or health-related
research involving humans did not aspire
to or attain reasonable availabil ity of a
new therapy. Furthermore, binding agree-
ments to make a new intervention reason-
ably available after national l icensing
were not always beneficial, as a less-
expensive or more effective and equally
expensive therapy might have been devel-
oped and approved in the meantime.
Finally, communities could still be exploited
even if the new intervention was made
reasonably available—for example, when
a new drug subsequently created large
financial profits.
Conceptually, as the argument went,
the focus on reasonable availability missed
the key ethical issue in exploitation.
According to Alan Wertheimer’s concept of
exploitation (Wertheimer, 1996), trans-
actions are exploitative because they do not
achieve fairness among interacting parties,
not because they fail to provide a particu-
lar type of benefit to a particular party.
Therefore, for the ethical conduct of a
study, it is essential to provide participants
and communities with a fair level of
research benefits—goods, services or
money—not just the particular benefit of
making the new intervention resonably
available (Participants, 2002, 2004).
According to this argument, the focus
on reasonable availabil i ty alone repre-
sents unjustified paternalism. Rather than
prescribing a particular benefit, commu-
nities themselves should be able to define
their benefits according to their needs,
values and priorities before engaging in a
research project. For both empirical and
conceptual reasons, the international
working group concluded that the prevail-
ing understanding of research benefits not
only failed to prevent or reduce exploita-
tion, but also increased paternalism in
relation to communities or populations
living under extremely constrained
socioeconomic conditions (Participants,
2002, 2004).
These arguments apply to research in
resource-poor settings where circumstances
entail important benefits for sponsors, and
where not sharing them would exacerbate
existing global injustices. However, the
resulting list of fair benefits is broad and dif-
ficult to navigate. Are all fair benefits equiv-
alent from an ethical perspective or are
some of their characteristics morally rele-
vant for their delineation and implementa-
tion? Moreover, although the fair-benefit
framework expands the range of possible
benefits, it provides little guidance on how
to put them into practice.
R
esearch benefits can be differentiated
by several characteristics. For exam-
ple, whether they are direct or indi-
rect—that is, whether the benefit is integral
for the conduct of research—whether they
benefit individuals or the collective,
whether they affect basic or non-basic
goods, and whether they are potential or
guaranteed. These characteristics all influ-
ence the delineation of research benefits
and help to assign responsibilities for their
provision. However, the distinction between
individual and collective benefits is particu-
larly relevant for the implementation of
research benefits.
Direct benefits usually affect individ-
uals; for example, when research partici-
pants are provided with medical treatment
during and after a study. Others—such as
community access to medical care, the
provision of health services or health-
research infrastructure, capacity building
or financial rewards—usually apply at a
collective level, but can entail individual
benefits in the long term. The distinction
between individual and collective research
benefits is important because it is not
straightforward that individuals would want
to assume the risks, burdens and inconve-
niences of research for collective benefits—
particularly if these benefits are indirect,
such as research-capacity building or
financial rewards.
Indirect collective benefits are not contro-
versial if they are provided in addition to
direct individual or collective benefits, or if
they balance collective burdens; for exam-
ple, by committing scarce resources such as
trained health personnel (Gbadegesin &
Wendler, 2006). However, in some
research—for example, epidemiological
studies—there might be no direct benefits
either to the individual or at the collective
level. Furthermore, it seems unrealistic to
evaluate collective benefits only with regard
to their effects on individuals (Participants,
2004), because some—for example,
research-capacity building—have long-term
effects with vague and uncertain individual
benefits. However, even if indirect collective
research benefits do not balance collective
risks or burdens and are of uncertain benefit
to the individual, they can be ethically defen-
sible when certain requirements are met. This
includes ensuring that the individual rights of
research participants are protected, the indi-
vidual risk–benefit ratio is favourable or the
net individual risks are negligible, individual
participants are aware of the collective bene-
fit scheme and agree with it, and the collec-
tive benefits have been defined and outweigh
collective risks from the perspective of the
community. We will now use the example of
research-capacity building to illustrate how
these requirements can be met in practice,
and the numerous conceptual and practical
difficulties involved in guaranteeing them.
The distinction between
individual and collective research
benefits is important because it is
not straightforward that
individuals would want to assume
the risks, burdens and
inconveniences of research for
collective benefits—particularly if
these benefits are indirect
science & society
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H
ealth research benefits communi-
ties by improving health, reducing
health inequities and helping to
develop sustainable communities (Lansang
& Dennis, 2004). Yet research-capacity
building is not usually an integral part of a
study. However, if adequately implemented,
research-capacity building can reduce the
risk of exploitation in international health
research. With a focus on implementation,
two main questions arise: how can the
above requirements for indirect collective
research benefits be met in practice and
how can research-capacity building then
be implemented?
There are few papers on the practical
aspects of community consultations in
clinical research (Diallo et al, 2005;
Dickert & Sugarman, 2005; Gbadegesin &
Wendler, 2006) and benefit-sharing
agreements in genetic research (Alvarez-
Casti l lo & Feinholz, 2006; Schuklenk &
Kleinsmidt, 2006). Moreover, to our
knowledge, none of these publications
have specifically investigated how
research benefits in clinical or health-
related studies should be negotiated.
However, it is possible to extrapolate gen-
eral steps for this procedure (Table 1),
and, at the same time, reveal some of the
unresolved conceptual and practical
questions about community involvement
in research.
B
efore any consultations or negotia-
tions begin, the community, which is
usually a group of people who are
linked by social ties, and who share com-
mon perspectives and a geographical
location (MacQueen et al, 2001), must be
identified. At this stage it is important to
distinguish between different types of
community according to particular
characteristics; guidelines written for one
community cannot be blindly applied to
another (Weijer & Emanuel, 2000). As the
example of so-called indigenous commu-
nities il lustrates, it can be difficult to
decide who can claim community mem-
bership and on what grounds (Schuklenk
& Kleinsmidt, 2006).
The next step is to identify the level of
community involvement in the research.
Usually, the benefits concern only those
who actually participate, and who bear
the risks and burdens. However, involve-
ment as a group—for example, by using
the community’s resources, focusing on
the community’s customs, traditions and
practices, or concentrating on a health
feature that is characteristic of the com-
munity—makes the claim for research
benefits even more poignant. Therefore,
the degree of community involvement
should be determined before negotiating
possible benefits.
After the community and its involvement
have been identified, legitimate representa-
tives should be identified by studying the
sociocultural structure, political and/or 
traditional leadership (Diallo et al, 2005).
Such studies require support from the com-
munity itself, assistance from anthropologists,
ethnologists, sociologists or political scien-
tists, and take time; it can be difficult to
determine who speaks for the community.
This process must also recognize potential
oppression within the community; the
choice of representatives should not reinforce
existing inequitable structures and relation-
ships, such as gender inequities (Alvarez-
Castillo & Feinholz, 2006).
As soon as negotiations begin, informa-
tion about the research must be provided,
including the basic elements of informed
consent, which comprise the purpose of
the research, potential benefits and risks to
participants and the community, proce-
dures for subject recruitment, and exclu-
sion and inclusion criteria (Diallo et al,
2005). Actual benefit negotiations are likely
to face a number of difficulties. First is the
complex task of assessing the risks, bur-
dens and benefits for individuals, the com-
munity and sponsors, in order to estimate a
fair distribution of benefits (Gbadegesin &
Wendler, 2006). At this stage, individual
and community risks must be carefully dis-
tinguished. Second, when the risks are
considered acceptable, community repre-
sentatives must determine community pri-
orities, values and needs in order to define
the corresponding benefits. This might not
be straightforward. Third, once the risks
and benefits have been circumscribed, it
can be difficult to determine the fairness of
an agreement, even when compared with
previous agreements (Participants, 2002,
2004). Fourth and finally, to assure proce-
dural fairness, independent mediating bod-
ies might be necessary to balance unequal
bargaining positions.
Along the way, it must be recognized
that benefit negotiations are dynamic.
Earlier agreements might have to be
changed according to the outcomes of 
the study. In cases of successive research
projects, it is preferable that community 
consultation takes place continuously
(Diallo et al, 2005). Making benefit 
agreements publicly available is also an
Table 1 | Determining research benefits for study participants and/or communities involved in research
Consulting the community to negotiate research benefits Steps and considerations
Which community? Identify the community according to community characteristics
Identify degree of community involvement in research
Study the chosen community with regard to sociocultural structure and
political/traditional leadership
Which community representatives? Identify legitimate representatives of the community, and do not reinforce existing
inequitable structures and relationships, such as gender inequities
How to negotiate? Provide information about the research
Assess risks, burdens and benefits for individual participants, the community and sponsors
Provide information about previous benefit agreements
Provide support for negotiations
Recognize that benefit negotiations are dynamic
What comes next? Make benefit agreements publicly available
...if adequately implemented,
research-capacity building can
reduce the risk of exploitation in
international health research
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important contribution towards establish-
ing a standard of fairness in international
research (Participants, 2004).
These general steps for negotiating
benefit agreements with communities
already present numerous practical prob-
lems, and further procedural and concep-
tual questions exist. What are valid cri-
teria for an informed community decision?
How can community coercion or induce-
ment be identified and prevented? What is
the equivalent of participant withdrawal
at the community level? How should ben-
efit agreements be integrated into national
health policy, particularly when they
include the provision of healthcare or
capacity building? As national authorities
have the primary responsibil i ty for popul-
ation health, they should be involved in
the negotiation and provision of indirect
collective research benefits. But what if
national authorities are corrupt or no
legitimate community representation can
be identified?
Nevertheless, once an indirect collec-
tive research benefit has been appropri-
ately negotiated, individual rights deserve
particular attention. Because of the con-
ceptual and practical questions that sur-
round the negotiations with communities,
protecting the rights of the individual study
participant remains a primary require-
ment for ethically defensible research.
This implies, most importantly, a
favourable individual risk–benefit ratio or
negligible net risks for individual partici-
pants, and their explicit agreement with
the collective benefit scheme as part of
the consent procedure.
P
rovided these general requirements
are met and a community has con-
cluded that research-capacity build-
ing should be an indirect benefit for study
participation, what are appropriate mea-
sures for its implementation in resource-
poor settings? We now show how various
facets of research-capacity building trans-
late into benefits to the community and/or
individuals (Table 2).
It is well recognized that addressing
local health needs is critical to improving
health in resource-poor settings and thereby
entails long-term benefits for communities
(Lansang & Dennis, 2004). Therefore,
assessment of local health needs and the
informed setting of research priorities
should be an integral part of research-
capacity building (Global Forum for
Health Research, 2004). As priority setting
is a long-term and continuous process,
creating research collaborations, and 
sharing knowledge and capabilities
between sponsors and/or researchers from
resource-rich and resource-poor settings,
is well-suited to improve health in poorer
countries (Global Forum for Health
Research, 2002).
The next step towards practically rele-
vant and high-quality research is to develop
a scientifically robust research project,
which ultimately benefits both individual
study participants and the community.
However, researchers in resource-poor set-
tings might not always be well trained in
research methodology, design or data
analysis. In international collaborative
research, a protocol is frequently designed
by a group in the sponsoring country and
only implemented by local researchers.
Although there are learning opportunities
even in these cases, it is important that local
researchers actively take part in the project
design and receive training in research
methodology in order to build long-term
research capacity.
The feasibil i ty of a research project is
also determined by local capacity, fund-
ing and facil i ties. When resources are
scarce, i t is often necessary to simplify
protocols, adapt equipment or use alter-
native techniques—provided that the sci-
entific validity of the adapted method can
be ensured (Harris, 2004). Furthermore,
feasibil i ty of a research project depends
on its acceptance by the community and
local authorities. Recent examples in
human immunodeficiency virus (HIV)
studies, such as the tenofovir (Viread®;
Gilead Sciences, Martinsried, Germany)
trial with commercial sex workers in
Cambodia, show that research projects
cannot be implemented without appro-
priate community involvement (Page-
Shafer et al, 2005). Research-capacity
building should allow researchers to
design a project that is scientifically
robust and feasible, and acceptable to 
the community.
Table 2 | Aspects of implementing research capacity building as a research benefit in clinical or health-related research
Area of research capacity building Goal Type of benefit Duration of benefit
Research priority setting Research responsive to health needs Collective – Long term
Practically relevant research
Research design High-quality research Individual, collective Short term Long term
Practically relevant research results
Staff development and infrastructure Efficient implementation of research Researchers, collective Short term Long term
Scientific and ethical review Good design and conduct of research Individual, collective – Long term
Protection of research participants
Publication and result communication High research impact Researchers, collective – Long term
Dissemination and advocacy High research impact Collective – Long term
Fundraising and grant writing More and better research Researchers, collective Short term Long term
Stewardship for research More and better research Researchers, collective Short term Long term
More and better researchers
Research partnerships Intellectual and material exchange Researchers Short term Long term
Profit sharing Financial gain Researchers, collective Short term Long term
...once an indirect collective





EMBO reports   VOL 8 | NO 1 | 2007 ©2007 EUROPEAN MOLECULAR BIOLOGY ORGANIZATION
viewp o in t
12
Considering the significant individual
and collective effects of research on
healthcare, it is also important that
research-capacity building promotes staff
development and improves working con-
ditions in health research, on both an insti-
tutional and a political level. If a scientific
career remains an unattractive option for
many young people in resource-poor
countries—owing to a lack of scientific
tradition and institutional support, low
wages, insufficient funding for research
projects and non-transparent recruitment
of research workers (Harris, 2004; Sitthi-
Amorn & Somrongthong, 2000)—research
cannot be implemented efficiently.
A
lthough the establishment of local
scientific and ethics review boards
has progressed in resource-poor set-
tings, concerns persist about the structure
of these committees, their standard opera-
tions and the expertise of their members.
Encouraging development and correct
functioning of ethical review committees is
one of the best ways to ensure that research
will actually serve the needs of the commu-
nity and protect individual study partici-
pants (WHO, 2000). Research-capacity
building should include training about the
ethical aspects of research, assistance in the
establishment of review boards, and pro-
grammes for continued education of board
members and scientists (Harris, 2004).
Publishing research results is a prereq-
uisite not only for making an impact on
clinical practices and policy making, but
also for advancing scientific careers and
obtaining future funding. However, it
might be difficult for researchers from
resource-poor settings to present their
findings in international journals, or to
establish esteemed local or regional jour-
nals. Lack of experience in presentation,
scientific writing and the English lan-
guage, as well as lack of an established
culture to publish research results (Harris,
2004), can lead researchers from
resource-poor settings to present their
work at conferences, in regional and
national databases or in reports to health
ministries—all of which are largely invis-
ible to the international scientific commu-
nity (Sadana & Pang, 2003). Work might
also remain unpublished for political rea-
sons. Research-capacity building could
therefore include training researchers in
scientific writing (Harris, 2004), and local
scientific journals could be promoted by
integrating them into online registers or
by establishing partnerships between
publishing organizations.
Publicly accessible research results can
lead to individual and collective benefits
by informing professional practices and
policy making; they should therefore be
disseminated and advocated beyond the
scientific community. However, dissemi-
nation might be difficult in countries where
health policy-making is often based on
opinion rather than evidence, and where
public access to information might be lim-
ited. To enhance the impact of research,
capacity building could include training in
dissemination and advocacy of scientific
results in communities and among health
policy makers. In order to incorporate sci-
entific evidence into policy making,
researchers and health officials should
establish regular communication and col-
laboration through workshops, consult-
ancy and so forth. Well-informed public-
health officials from resource-poor countries
are also expected to have greater influence
on political debates and decisions on 
global health governance (Sitthi-Amorn &
Somrongthong, 2000).
Securing funds is necessary to sustain
research projects that address local health
needs. Researchers from resource-poor
countries might have l imited experience
in preparing competitive grant proposals
or might even be unaware of funding
opportunities (Harris, 2004). Research-
capacity building could therefore also
provide support in effective fundraising
and grant writing.
Many countries have established national
medical or health research coordination
bodies to guarantee transparent and
accountable allocation of funds, quality of
research and alignment of research funding
with national research priorities to ensure
that communities benefit. Despite the need
for such transparency, similar bodies do
not exist in many resource-poor countries
(Sadana & Pang, 2003). Research-capacity
building could therefore help to establish or
advance national authorities to oversee and
coordinate health research.
The successful conduction and imple-
mentation of research requires input from
various scientific disciplines, the commu-
nity, and the political and private sectors.
To advance the quality of research, capac-
ity building could promote networking
and scientific partnerships at national and
international levels (Sitthi-Amorn &
Somrongthong, 2000), as well as intersec-
toral partnerships between researchers
and the community, civi l society organi-
zations, national health authorities and
the private sector.
In some cases, considerable financial
profits are gained from research results,
and sharing these or intellectual property
rights can benefit local researchers and
the community. However, scientists—just
l ike communities—might be unprepared
to negotiate such agreements. Research-
capacity building could therefore help to
develop innovative ways of fair profit
sharing, as well as subsequent profit
investment.
To conclude, providing indirect collec-
tive research benefits can be a genuine
way to reduce exploitation in international
research. However, as the example of
research-capacity building shows, the
concept is riddled with conceptual and
practical questions, particularly regarding
negotiations with communities. In the
end, protecting the rights of individual
participants remains a primary require-
ment for ethically defensible research in
resource-poor countries or regions.
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